输注前18F-FDG PET/CT对接受嵌合抗原受体T细胞治疗的B细胞非霍奇金淋巴瘤患者的预后与毒性预测
本回顾性研究纳入133例接受CAR-T治疗且输注前有18F-FDG PET/CT图像的B细胞非霍奇金淋巴瘤患者,中位随访20.8个月。SUVmax( cutoff 15.65)是与无进展生存、总生存和客观缓解相关的独立代谢参数,且SUVmax和Deauville评分与细胞因子释放综合征发生呈弱正相关。作者认为输注前PET/CT的SUVmax可能有助于指导CAR-T治疗患者选择和预测潜在副作用。
要点
- SUVmax≥15.65组中位PFS为9.13个月(95%CI 0.11-18.16),SUVmax<15.65组PFS未达到(P=0.006)。
- SUVmax≥15.65组平均OS为26.89个月,低于SUVmax<15.65组的45.14个月(P=0.010)。
- SUVmax≥15.65组达到客观缓解的OR为0.173(95%CI 0.056-0.539)。
核心结论
- 治疗前PET/CT参数SUVmax似乎是疗效和预后的有前景预测因素,并与细胞因子释放综合征的发生相关。
- 作者认为治疗前PET/CT扫描的这一代谢参数可能作为指导CAR-T治疗患者选择和预测潜在副作用的有价值工具。
研究设计与样本
- 回顾性研究,纳入接受CAR-T治疗且有输注前18F-FDG PET/CT图像的B细胞非霍奇金淋巴瘤患者。
- 共纳入133例患者,记录SUVmax、代谢肿瘤体积(MTV)、总病灶糖酵解(TLG)及多种临床和实验室指标。
- 主要终点为无进展生存(PFS)和总生存(OS),采用Kaplan-Meier法估计,并报告PET/CT参数与客观缓解(OR)及细胞因子释放综合征(CRS)的相关性。
- 中位随访时间为20.8个月。
主要发现
- SUVmax(cutoff值15.65)是与PFS、OS和OR相关的独立代谢参数。
- SUVmax≥15.65组中位PFS为9.13个月(95%CI 0.11-18.16),SUVmax<15.65组PFS未达到(P=0.006)。
- SUVmax≥15.65组平均OS为26.89个月,SUVmax<15.65组为45.14个月(P=0.010)。
- SUVmax≥15.65组达到OR的OR为0.173(95%CI 0.056-0.539)。
- 与PFS相关的其他因素包括ECOG-PS、B症状、大肿块和结外 sites,而IPI和LDH与OS相关;SUVmax和Deauville评分与CRS发生呈弱正相关。
关键数值与推荐
- SUVmax cutoff值为15.65。
- SUVmax≥15.65组中位PFS为9.13个月(95%CI 0.11-18.16),SUVmax<15.65组PFS未达到(P=0.006)。
- SUVmax≥15.65组平均OS为26.89个月,SUVmax<15.65组为45.14个月(P=0.010)。
- SUVmax≥15.65组达到OR的OR为0.173(95%CI 0.056-0.539)。
临床怎么用
- 原文未据此给出推荐。
- 作者认为治疗前PET/CT的SUVmax可能作为指导CAR-T治疗患者选择和预测潜在副作用的有价值工具。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The aim of this study was to evaluate the value of 18 F-FDG PET/CT in predicting outcomes and toxicity for patients with B-cell non-Hodgkin lymphoma (B-NHL) who underwent chimeric antigen receptor T (CAR-T) cell therapy. METHODS: This retrospective study included B-NHL patients who underwent CAR-T therapy and had pre-infusion 18 F-FDG PET/CT images. We recorded SUVmax, metabolic tumor volume (MTV), total lesion glycolysis (TLG), and various clinical and laboratory indexes. The primary endpoints were progression-free survival (PFS) and overall survival (OS). PFS and OS were estimated using the Kaplan-Meier method. In addition, we reported the correlation between PET/CT parameters and the objective response (OR), as well as cytokine release syndrome (CRS). RESULTS: A total of 133 patients were enrolled in this study. The median follow-up duration was 20.8 months. SUVmax (with a cutoff value of 15.65) emerged as an independent metabolic parameter associated with PFS, OS, and OR. Patients with SUVmax ≥15.65 had a median PFS of 9.13 months (95% CI: 0.11-18.16), while the PFS for those with SUVmax<15.65 was not reached ( P =0.006). Furthermore, patients with SUVmax ≥15.65 exhibited significantly shorter average OS compared with those with SUVmax<15.65 (26.89 mo vs. 45.14 mo, P =0.010). In addition, the odds ratio for achieving an OR in patients with SUVmax ≥15.65 was found to be lower at 0.173 (95% CI: 0.056-0.539). Other factors associated with PFS included ECOG-PS, B symptoms, bulky mass, and extranodal sites, whereas IPI and LDH were associated with OS. Furthermore, SUVmax and Deauville scores showed a weak positive correlation with the occurrence of CRS. CONCLUSIONS: The pretreatment PET/CT parameter SUVmax appears to be a promising predictive factor for efficacy and prognosis, as well as being associated with the occurrence of CRS. Consequently, we can conclude that this metabolic parameter from pretreatment PET/CT scans may serve as a valuable tool in guiding patient selection for CAR-T therapy and predicting potential side effects.
引用
- Yao X, Wang H, Lei X, et al. Pre-infusion 18 F-FDG PET/CT for Prognostic and Toxicity Prediction in B-cell Non-Hodgkin Lymphoma Patients Undergoing Chimeric Antigen Receptor T-cell Therapy. Clin Nucl Med. 2025. PMID: 40197422. doi:10.1097/RLU.0000000000005888
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。